---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-044242"
form_type: "8-K"
ticker: null
cik: "0001831874"
company_name: "Iris Acquisition Corp"
filed_at: "2024-04-05T23:59:59+00:00"
generated_at: "2026-06-04T01:56:07.998748+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Iris Acquisition Corp extends business combination deadline with Liminatus Pharma to July 31, 2024

## Summary
- Third amendment to business combination agreement pushes outside date from March 9, 2024 to July 31, 2024.
- PIPE equity and convertible note subscription agreements also extended to July 31, 2024.
- All other terms of the BCA and subscription agreements remain unchanged.
- This is the third extension since the original BCA was signed in November 2022.

## SEC filing metadata
- accession: 0001104659-24-044242
- form_type: 8-K
- cik: 0001831874
- company_name: Iris Acquisition Corp
- filed_at: 2024-04-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831874/000110465924044242/0001104659-24-044242-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831874/000110465924044242/tm2411213d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-044242
- JSON: https://secwatch.observer/filing/0001104659-24-044242.json
- Plain text: https://secwatch.observer/filing/0001104659-24-044242.txt

## Key facts
- Material Agreements
  Iris Acquisition Corp amended Third BCA Amendment with Liminatus Pharma, LLC (effective 2024-03-09).
  - Action: amendment
  - Agreement: merger
  - Counterparty: Liminatus Pharma, LLC
  - Effective: 2024-03-09
  source text: On March 9, 2024, Iris Acquisition Corp, a Delaware corporation (“we,” “our,” or “Iris”), Iris Parent Holding Corp., a Delaware corporation (“ParentCo”) and Liminatus Pharma, LLC, a Delaware limited liability company (“Liminatus”), entered into a third amendment (the “Third BCA Amendment”) to the Business Combination Agreement
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831874/000110465924044242/0001104659-24-044242-index.htm
- Material Agreements
  Iris Acquisition Corp amended Second Amendment to Convertible Note PIPE with PIPE subscriber (effective 2024-03-09).
  - Action: amendment
  - Agreement: notes offering
  - Counterparty: PIPE subscriber
  - Effective: 2024-03-09
  source text: ParentCo, Iris and the PIPE subscriber entered into a second amendment (the “Second Amendment to Convertible Note PIPE”) to the Convertible Note Subscription Agreement
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831874/000110465924044242/0001104659-24-044242-index.htm
- Material Agreements
  Iris Acquisition Corp amended Second Amendment to Equity PIPE with PIPE subscriber (effective 2024-03-09).
  - Action: amendment
  - Agreement: equity purchase
  - Counterparty: PIPE subscriber
  - Effective: 2024-03-09
  source text: ParentCo, Iris and the PIPE subscriber entered into a second amendment (the “Second Amendment to Equity PIPE”) to the Equity Subscription Agreement
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831874/000110465924044242/0001104659-24-044242-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.